Company intelligence / Profile preview

Neopharma Japan

Chiyoda, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Neopharma Japan is a pharmaceutical company specializing in the research, development, and manufacturing of 5-Aminolevulinic Acid (5-ALA) based products. As a subsidiary of the global Neopharma group, the company focuses on leveraging 5-ALA for diverse applications, including photodynamic diagnosis (PDD) for oncology, metabolic health, and infectious diseases. Their flagship product, ALAGLIO, is used for the intraoperative visualization of malignant gliomas and bladder cancer. The company operates a dedicated manufacturing facility in Japan and collaborates with academic institutions to expand the therapeutic potential of mitochondrial medicine.

Therapeutic areas: EndocrinologyInfectious DiseasesRare DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

SBI PharmaceuticalsNagasaki University

Beyond the preview

Go deeper on Neopharma Japan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neopharma Japan.

Explore the full profile